ストックスクリーナーアプリを入手
0.4946
3.06%
-0.0156
アフターアワーズ：
.49
-0.0046
-0.93%
Sangamo Therapeutics Inc (SGMO) 最新ニュース
What analysts say about Sangamo Therapeutics Inc. stockBreakout portfolio performance - jammulinksnews.com
Is Sangamo Therapeutics Inc. a good long term investmentExceptional trading results - PrintWeekIndia
What drives Sangamo Therapeutics Inc. stock priceTremendous wealth creation - jammulinksnews.com
Sangamo Therapeutics Inc. Stock Analysis and ForecastAccelerated earnings growth - jammulinksnews.com
Why Sangamo Therapeutics Inc. stock is on top investor watchlistsAnalyst Grade Signals - beatles.ru
Hemoglobinopathies Market Set to Witness Significant Growth - openPR.com
Sangamo Therapeutics prices $23M securities offering - MSN
Why Sangamo Therapeutics Inc. stock attracts strong analyst attentionMinimized Risk Trading Plan - beatles.ru
H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data - Insider Monkey
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN) - The Globe and Mail
Sangamo rises after trial data for Fabry disease therapy - MSN
Sangamo Therapeutics (SGMO) Receives Reiterated "Buy" Rating fro - GuruFocus
Transcat: HC Wainwright Reiterates Buy, Raises PT to $116 from $116. - AInvest
Sangamo's (SGMO) Promising Phase 1/2 Gene Therapy Results for Fa - GuruFocus
Sangamo reports positive results for Fabry disease gene therapy By Investing.com - Investing.com India
Sangamo Therapeutics shares fall 1.56% in after-hours after reporting positive topline results from Phase 1/2 STAAR study. - AInvest
Sangamo Biosciences Approves Amendments to Equity Plan - TipRanks
Treg Cell-Based Therapies Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Rapa Therapeutics, Orca Bio, Caladrius Biosciences, Sangamo Therapeut - The Globe and Mail
Certain Warrants of Sangamo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2025. - MarketScreener
Palmetto Grain Brokerage - Palmetto Grain Brokerage
H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN
Two Sigma Investments LP Acquires 698,296 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Zenopa
Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com UK
Lazard Asset Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Captrust Financial Advisors Makes New $30,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
StockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO) - Defense World
Barclays Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World
Sangamo Biosciences’ Earnings Call: Progress Amid Challenges - TipRanks
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | SGMO Stock News - GuruFocus
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock New - GuruFocus
Sangamo Biosciences Announces $23 Million Share Offering - TipRanks
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock News - GuruFocus
Sangamo Therapeutics (SGMO) Projects 2025 Operating Expenses Ami - GuruFocus
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights - GuruFocus
Market Setbacks: Major Stocks Face Financial Hurdles - Finimize
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics (SGMO) Announces $23M Capital Raise - GuruFocus
0.87%
0.17%
大文字化:
|
ボリューム (24 時間):